Common

CHOP Researchers Find Rate of Fatal Opioid Poisonings Among Children More Than Doubled Over 13-Year Span

Retrieved on: 
Wednesday, March 8, 2023
Online, Child, Emergency medicine, The Poison Control Center, MSCE, Pediatric emergency medicine, Allergy, Brain Injury Research Institute, Death, Poison control center, Division, Common, Children's Hospital of Philadelphia, Fatality, Poisoning, Pediatrics, Pain, Heroin, Hospital, Research, Associate, Naloxone, CHOP, National Center for Health Statistics, Liquor, Birth control, MD

PHILADELPHIA, March 8, 2023 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) found opioids were responsible for more than half of all fatal poisonings in children ages 5 and younger, more than double the proportion of fatal poisonings caused by opioids in 2005. Additionally, over-the-counter drugs still contribute to fatal poisonings in this age group despite increased regulation. The findings, published today in the journal Pediatrics, underscore the need for improved intervention to prevent further fatal poisonings.

Key Points: 
  • Additionally, over-the-counter drugs still contribute to fatal poisonings in this age group despite increased regulation.
  • The findings, published today in the journal Pediatrics, underscore the need for improved intervention to prevent further fatal poisonings.
  • More than half of all reported poisonings affect children ages 5 and younger and have the highest rate of emergency department visits for unintentional drug-related poisonings.
  • Studying fatal poisonings in young children on a broad scale in the U.S. has been challenging for researchers.

Kaleyra to Effect 1-for-3.5 Reverse Stock Split

Retrieved on: 
Monday, March 6, 2023
Transfer, Bangladesh Securities and Exchange Commission, Reverse stock split, Security (finance), Common stock, NYSE, CST, Special-purpose acquisition company, Communication, Second Amendment to the United States Constitution, Kaleyra, Special, The Company, CUSIP, Letter, KLR, Common

As a result of the Reverse Stock Split, every three and one-half (3.5) shares of Common Stock issued and outstanding will be converted into one (1) share of Common Stock.

Key Points: 
  • As a result of the Reverse Stock Split, every three and one-half (3.5) shares of Common Stock issued and outstanding will be converted into one (1) share of Common Stock.
  • The Reverse Stock Split will not reduce the number of authorized shares of Common Stock or change the par values of the Common Stock.
  • The Reverse Stock Split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of the Company's shares of Common Stock (except to the extent that the Stock Split would result in some of the stockholders receiving an additional fractional share).
  • The reverse stock split will not affect the number of authorized shares of common stock.

Chinese modernization makes broader prospects for common development of mankind

Retrieved on: 
Sunday, March 5, 2023
Summit, Poverty, United, Belt, APEC, People's Daily, Belt and Road Initiative, Government, Civilization, Stagnation, United Nations, Sustainability, Common, Shipbuilding, Renewable energy, Sales

Achieving common prosperity for all is one of the essential requirements of Chinese modernization.

Key Points: 
  • Achieving common prosperity for all is one of the essential requirements of Chinese modernization.
  • While pursuing its own development, China is constantly working for the common prosperity of the world with concrete actions.
  • To make global development more balanced, China proposed the Global Development Initiative, which has been supported by over 100 countries and international organizations.
  • On its way to modernization, China stands ready to provide more resources for global development cooperation and work with all other parties to build a global community of development, so as to make broader prospects for the common development of mankind.

W.T.B. Financial Corporation Announces Share Repurchase Authorization

Retrieved on: 
Saturday, March 4, 2023
Security (finance), Public company, An Act to exempt a particular class of securities from the Securities and Exchange Act, Share repurchase, Common, Financial adviser

Financial Corporation has announced the authorization of a share repurchase plan for up to $15.0 million of Class B common stock effective March 3, 2023, and continuing through February 28, 2024.

Key Points: 
  • Financial Corporation has announced the authorization of a share repurchase plan for up to $15.0 million of Class B common stock effective March 3, 2023, and continuing through February 28, 2024.
  • The stock repurchase plan authorized on March 1, 2022, has terminated.
  • Common share repurchases under the new plan, if any, may be made from time to time on the open market through broker dealers or in privately negotiated transactions, at the discretion of Company management.
  • The extent to which the Company purchases shares and the timing of any such purchases will depend upon a variety of factors, including market conditions and relevant corporate considerations.

dMY Technology Group, Inc. VI Announces Extension of Expiration Date of Tender Offer and Release of dMY VI Audited Annual Financial Statements for 2022

Retrieved on: 
Friday, March 3, 2023
Environment, Technology, Finance, Other Energy, Other Technology, Professional Services, Sustainability, Green Technology, Energy, Transfer, Letter of transmittal, Tender, Tax, Common, Bank statement, Mini-tender offer, Purchase price allocation, Tender offer, Business analyst, Letter, Interest on Lawyer Trust Accounts, Trust, Annual report, Accounting, News, Bangladesh Securities and Exchange Commission, Excise tax in the United States, Common stock, Excise, Multimedia, NYSE, Trump Media & Technology Group, VI, Calendar, Cryptocurrency

As amended, the Tender Offer will now expire at 5:00 p.m. New York City time, on Friday, March 31, 2023, unless further extended or earlier terminated.

Key Points: 
  • As amended, the Tender Offer will now expire at 5:00 p.m. New York City time, on Friday, March 31, 2023, unless further extended or earlier terminated.
  • dMY VI shareholders may withdraw shares they have previously tendered at any time prior to the extended expiration date of the Tender Offer.
  • Banks and brokers may call the information agent at +1 (203) 658-9400.
    dMY VI today also announced that it has released its audited annual financial statements for 2022.
  • dMY VI’s audited annual financial statements for 2022 can be found in the Company’s current report on Form 8-K filed with the SEC on March 3, 2023, and available at www.sec.gov.

PIMCO Energy and Tactical Credit Opportunities Fund Declares Quarterly Common Share Distributions

Retrieved on: 
Wednesday, March 1, 2023
Character, Annual report, FDIC, Stock, PIMCO, Leg, Sale, Federal Reserve Board of Governors, Transport, Common, Security (finance), NAV, Government, Risk management, Internal Revenue Service, MLP, Tax, Investment Company Act of 1940, Trustee, Risk, Policy, Bank statement, Natural gas, Record, New York Stock Exchange, Average revenue per user, Calendar, Investment, Life insurance, Bank, Fund

Final determination of a distribution’s tax character will be provided to shareholders when such information is available.

Key Points: 
  • Final determination of a distribution’s tax character will be provided to shareholders when such information is available.
  • Any recharacterization of payments made or received by the Fund pursuant to derivatives potentially could affect the amount, timing or character of Fund distributions.
  • If you sell your common shares of the Fund, the price received may be more or less than your original investment.
  • The Fund is non-diversified, which means that it may invest its assets in a smaller number of issuers than a diversified Fund.

Mount Sinai Expert Urge Colon Cancer Awareness and Education to Reverse Decline in Screening Rates during Pandemic

Retrieved on: 
Wednesday, March 1, 2023
Colonoscopy, DNA, MD, CDC, Diagnosis, Colorectal cancer, Disease, Genetic counseling, Risk, Black, Inflammatory bowel disease, Rectum, Patient, Hereditary nonpolyposis colorectal cancer, CT, Mount Sinai Hospital (Manhattan), FIT, Diet, Child, FAP, Icahn School of Medicine at Mount Sinai, Common, Korea Disease Control and Prevention Agency, African Americans, Exercise, CDN, Ulcerative colitis, FOBT, Tobacco, Vegetable, Diarrhea, Endoscopy, MPH, Woman, IBD, Crohn's disease, Constipation, Obesity, Dietary supplement, Liquor, Large intestine, RD

NEW YORK, March 1, 2023 /PRNewswire-PRWeb/ -- Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States. Although highly treatable and preventable, about 140,000 Americans are diagnosed and more than 50,000 people die each year, according to the Centers for Disease Control and Prevention (CDC). The United States Preventative Task Force recommends starting age of screening from 45 to 50.

Key Points: 
  • NEW YORK, March 1, 2023 /PRNewswire-PRWeb/ -- Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States.
  • In an effort to increase awareness and screening, Mount Sinai has expanded Colorectal Cancer Awareness Initiatives across all eight hospital sites during the month of March to provide patients with access to health professionals to discuss prevention, screening options, and risk factors.
  • However, colorectal cancer disproportionately affects the Black community, where the rates are the highest of any racial/ethnic group in the US.
  • African Americans are 20% more likely to get colorectal cancer and about 40% more likely to die from colorectal cancer than most other groups.

Government of Canada supports seniors in Long Term Care by helping to ensure they access safe and quality care

Retrieved on: 
Wednesday, March 1, 2023
Government of Canada, Colleges and Institutes Canada, CSA, OHSAS 18001, NOS, Safety, Government, Learning, Curriculum, Family, HSO, The Honourable, Workforce, Ageing, Mental, COVID-19, CSA Group, Patient, Long-term care, Personal care, Culture, Common, Home care, Environment, Safe, Caregiver, Dignity, LTC, Mental health, Palliative care, Nursing, Health

On February 7, 2023, the Government of Canada announced an investment of $198.6 billion over 10 years to improve health care services for Canadians.

Key Points: 
  • On February 7, 2023, the Government of Canada announced an investment of $198.6 billion over 10 years to improve health care services for Canadians.
  • Helping Canadians age with dignity, closer to home, with access to home care or safe long-term care (LTC) remains a priority.
  • Today, the Honourable Jean-Yves Duclos, Minister of Health, and the Honourable Kamal Khera, Minister of Seniors, reiterated the Government's commitment to help ensure quality, safe and respectful care for seniors in LTC homes across Canada.
  • "All seniors deserve to live in dignity with access to home care or safe and quality care in a long-term care facility.

The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE

Retrieved on: 
Wednesday, March 1, 2023
Headache, Safety, Thrombosis, Lower respiratory tract infection, ASX, Disease, American Academy of Allergy, Asthma, and Immunology, Annual general meeting, Patient, AAAAI, Attack, HAE, Hereditary angioedema, CSL, Common, Bleeding, Physician, American Academy, Pharmaceutical industry, Lancet

KING OF PRUSSIA, Pa., March 1, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL;USOTC:CSLLY), announced that The Lancet has published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE). The Lancet paper provides detailed data on the Phase 3 study, which were recently presented during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. The study met its primary and secondary endpoints, demonstrating that monthly subcutaneous injections of garadacimab significantly reduced the attack rate compared to placebo in patients with HAE.

Key Points: 
  • The Lancet paper provides detailed data on the Phase 3 study, which were recently presented during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas.
  • The study met its primary and secondary endpoints, demonstrating that monthly subcutaneous injections of garadacimab significantly reduced the attack rate compared to placebo in patients with HAE.
  • The study also showed that garadacimab demonstrated a favorable safety profile with a similar frequency of treatment-emergent adverse events across garadacimab and placebo arms.
  • The development of garadacimab reflects our commitment to providing life changing medicines for patients with HAE and for the physicians who treat them."

TETRA Technologies, Inc. Adopts Tax Benefits Preservation Plan

Retrieved on: 
Wednesday, March 1, 2023
Carbon, Food, Corporate finance, Stock appreciation right, Lithium, TETRA, International tax planning, NYSE, Chemistry, Cyprus Securities and Exchange Commission, Calcium chloride, Holding company, Tax attribute, Security (finance), Common, Tax, Bromine, CFO, Multimedia, Common stock, CO2, Internal Revenue Code, Rights, Cryptocurrency, Life insurance

THE WOODLANDS, Texas, March 1, 2023 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced today that its Board of Directors has adopted a Tax Benefits Preservation Plan (the "Tax Plan") intended to preserve the availability of the Company's existing net operating loss carryforwards ("NOLs") and other tax attributes (collectively, the "Tax Attributes").

Key Points: 
  • THE WOODLANDS, Texas, March 1, 2023 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced today that its Board of Directors has adopted a Tax Benefits Preservation Plan (the "Tax Plan") intended to preserve the availability of the Company's existing net operating loss carryforwards ("NOLs") and other tax attributes (collectively, the "Tax Attributes").
  • The Tax Plan reduces the likelihood that changes in the Company's investor base would limit the Company's future use of its Tax Attributes, which would significantly impair the value of such Tax Attributes.
  • The Tax Plan is intended to ensure the Tax Attributes remain available to the Company into the future.
  • The Tax Plan is similar to tax benefit preservation rights plans that are adopted by other public companies with significant Tax Attributes.